Pancreatic Cancer Therapeutics in Major Developed Markets to 2021

1
Pancreatic Cancer Therapeutics in Major Developed
Markets to 2021 - Strong Late Stage Pipeline
Holds Promise for Increasingly Diverse Market
Landscape
(Type, Mode of action, Crop Type and Geography) -
Size, Share, Global Trends, Company Profiles,
Demand, Insights, Analysis, Research, Report,
Opportunities, Segmentation and Forecast, 2013 -
2020
TELEPHONE [phone]E-MAIL
sales_at_researchbeam.com
Published on Oct 2014
2


Report Overview

• Scope
• Global revenues for the PC market are forecast to
  rise at a moderate CAGR of 7.6 from 1.746bn in
  2014 to 2.92bn in 2021.
• - What factors are driving the market growth?
• - How can the factors limiting growth be
  overcome in the future?
• The variation in mechanism of action has shifted
  away from the traditional chemotherapies, which
  dominate the marketed products, but account for
  only 7 of the pipeline. 44 of the pipeline are
  drugs inhibiting signal transduction.
• - What are the dynamics of the remaining 49 of
  the pipeline?
• - How does this reflect the need for novel
  targeted therapies?
• Key mechanisms of action across the pipeline
  include cancer immunotherapies against IAP repeat
  containing proteins, whole cell vaccines and
  targeted therapies against the PI3K/Akt/mTOR
  pathway.
• - What is the scientific rationale behind these
  targets?
• Several drugs are expected to be approved during
  the forecast period TH-302, ruxolitinib
  phosphate, HyperAcute Pancreas, G17DT and
  clivatuzumab tetraxetan. However, their sales
  will be limited by their expected high costs.
• Read More At http//www.researchbeam.com/pancreat
  ic-cancer-therapeutics-in-major-developed-to-2021-
  strong-late-stage-pipeline-holds-promise-for-incre
  asingly-diverse-landscape-market

3


Table of Content
1 Table of Contents 6 1.1 List of Tables 8 1.2
List of Figures 9 2 Introduction 11 2.1 Disease
Introduction 11 2.2 Epidemiology 11 3 Commercial
and Clinical Prospects of Marketed Products
24 3.1 Approved Products 24 3.2 Off-Label
Products 30 4 Pipeline for Pancreatic Cancer
Therapeutics 36 4.1 Overview by Phase and
Molecule Type 37 4.2 Overview by Molecular Target
38 5 Market Forecast to 2021 72 5.1 Global
Market 73 5.2 North America 74
4


Table of Content
6 Drivers and Barriers 87 6.1 Drivers 87 6.2
Barriers 89 7 Strategic Consolidations 91 7.1
Major Co-Development Deals 91 7.2 Major Licensing
Deals 95 8 Appendix 100 8.1 All Pipeline Drugs
by Phase 100 8.2 Market Forecasts to 2020
114 Enquire At http//www.researchbeam.com/pa
ncreatic-cancer-therapeutics-in-major-developed-to
-2021-strong-late-stage-pipeline-holds-promise-for
-increasingly-diverse-landscape-market/enquire-abo
ut-report
5



FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/pancreatic-cancer-ther
apeutics-in-major-developed-to-2021-strong-late-st
age-pipeline-holds-promise-for-increasingly-divers
e-landscape-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone] DIRECT 1 (503)
894-6022E-MAIL sales_at_researchbeam.com